





| IN - HOUSE PROGRAMS | | CURRENT STAGE OF DEVELOPMENT | | | |
|-----------------------------------|--|------------------------------|------------|--------------------|--------------------|
| Program/Molecule Name | Investigational Indication | Pre-Clinical | Phase 1/2a | Registration Trial | Initial Indication |
| OROTECAN® (oral irinotecan HCl) | Pediatric & Adult Malignancies | | | | Ewing Sarcoma |
| EO-3001 - ARID1a Targeted Therapy | Ovarian Clear Cell Cancer & Solid Tumors | | | | OCCC |
| EO-4426 (tezacitabine) | Solid Tumors & Hematologic Malignancies | | | | Solid Tumors |

| PARTNERED PROGRAMS | | CURRENT STAGE OF DEVELOPMENT | | | | |
|--------------------------------|----------------------------|------------------------------|------------|--------------------|------------------------|---|
| Program/Molecule Name | Investigational Indication | Pre-Clinical | Phase 1/2a | Registration Trial | Initial Indication | Development Partner |
| EO-1001 Pan-ErbB inhibitor | Solid Tumors | | | | PARP-resistant cancers |  |
| DNA-Damage Response Inhibitors | Solid Tumors | | | | TBD |  |

* ErbB-1(EGFR) positive cancer, ErbB-2(HER2) positive cancer, ERbB-4 (HER4) positive cancer